MLND - Millendo Therapeutic...

Millendo Therapeutics, Inc.

MLND

NASDAQ

Inactive Equity

Millendo Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing novel treatments for orphan endocrine diseases in the United States. Its lead product candidates include livoletide, a potential treatment for Prader-Willi syndrome; nevanimibe, a potential treatment for patients with classic congenital adrenal hyperplasia; and MLE-301, a neurokinin 3-receptor antagonist for the treatment of vasomotor symptoms in menopausal women. The company is headquartered in Ann Arbor, Michigan.

1.06 USD

-0.06000006 (-5.66%)

Overview Profile Financial Statements Financial Ratios Chart Analysis News Corporate Actions DCF

PPE Schedule

Year

2020

2019

2018

2017

Gross PPE

2.16M

3.33M

3.11M

Annual Depreciation

1.1M

1.05M

32k

1.65M

Capital Expenditure

-26k

-397k

-36k

-158k

Net PPE

1.08M

2.68M

1.62M

All figures are in USD.

All Income Statement Balance Sheet Statement Cash Flow Statement Retained Earning Schedule PPE Schedule Intangible and Goodwill Schedule

FMP

Home Terms of Service Privacy Policy Blog Careers FAQs Contact Us

API

Documentation Pricing Formulas Market Indexes

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.